Scil Proteins signs partnership to research cancer therapies
Will work with Martin Luther University Halle-Wittenberg
Scil Proteins, a German biotech company focused on the research, development and production of recombinant proteins, has agreed with the Martin Luther University Halle-Wittenberg to research new therapies for gastrointestinal tumours.
The project will be run by Professor Thomas Seufferlein, head of the University Hospital’s gastroenterology clinic, and will focus on the discovery and characterisation of disease-related molecular structures. Scil Proteins will then use its proprietary Affilin platform to identify effective therapeutics and advance them into further clinical development.
Scil Proteins’ Affilin therapeutics are scaffold proteins derived from the human protein Ubiquitin. The company says Affilin molecules are high affinity binders with excellent target specificity. The Affilin platform has successfully delivered target specific molecules, which have subsequently shown activity in animal models, within only a few months.
Ulrike Fiedler, ceo of Scil Proteins, said: ‘We hope that the project will allow us to develop new therapeutic options for patients suffering from gastrointestinal cancer.’
